Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? reply.
Authors
Clarke, Noel WAffiliation
The Christie NHS FT, ManchesterIssue Date
2018
Metadata
Show full item recordCitation
Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer? reply. 2018, 19(9):E438-E438 Lancet OncolJournal
Lancet OncologyDOI
10.1016/S1470-2045(18)30616-8Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/S1470-2045(18)30616-8